LBS

Analyst Comment

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Originally granted approval in the US, in 2017, Ozempic has subsequently obtained approval for three distinct dosages to treat type 2 diabetes.

GlobalData Healthcare

Features

BYJU’s, India’s most valuable unicorn, is giving the UK an education in AI technology

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

BYJU’s, India’s most valuable unicorn, is giving the UK an education in AI technology

Leading account and intent-based sales and marketing providers and technology solutions for the pharmaceutical industry

Leading sales and marketing intent data, database and data enrichment providers and technology solutions for the pharmaceutical industry

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief